Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Akito Tsutsumi, Eiji Matsuura, Kenji Ichikawa, Atsushi Fujisaku, Masaya Mukai, Seiichi Kobayashi, Takao Koike

Research output: Contribution to journalArticlepeer-review

203 Citations (Scopus)


Objective. To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to β2-glycoprotein I (β2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-β2GPI antibody and clinical manifestations in SLE patients. Methods. IgG and IgM anti-β2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. Results. The values of anti-β2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-β2GPI assay was more useful in distinguishing β2GPI-dependent aCL from β2GPI-independent aCL. The presence of IgG anti-β2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-β2GPI may fluctuate with disease activity. Conclusion. The results suggest that pathogenic aCL is directed against structurally altered β2GPI and that enzyme immunoassay for anti-β2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.

Original languageEnglish
Pages (from-to)1466-1474
Number of pages9
JournalArthritis and Rheumatism
Issue number9
Publication statusPublished - Sept 1996
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)


Dive into the research topics of 'Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this